Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines

Robert J. Schmittling*, Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, John H. Sampson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunotherapy. Although endogenous humoral responses to EGFRvIII have been reported in patients with EGFRvIII-expressing breast cancer, it is not known whether de novo responses can be generated or endogenous responses enhanced with an EGFRvIII-specific vaccine. To assess this in clinical trials, we have developed and validated an immunoassay to measure and isolate anti-EGFRvIII and anti-KLH antibodies from the serum of patients vaccinated with an EGFRvIII-specific peptide (PEPvIII) conjugated to keyhole limpet hemocyanin (KLH). Using magnetic beads with immobilized antigen we captured and detected anti-EGFRvIII and anti-KLH antibodies in serum from patients before and after vaccinations. Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (> 4 μg/mL) and KLH could be induced after vaccination with PEPvIII-KLH.

Original languageEnglish (US)
Pages (from-to)74-81
Number of pages8
JournalJournal of Immunological Methods
Issue number1
StatePublished - Nov 30 2008
Externally publishedYes


  • Beads
  • Glioblastoma
  • Humoral response
  • KLH
  • Magnetic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines'. Together they form a unique fingerprint.

Cite this